TL;DR: Cigna Healthcare modified MM 0577 for esophageal mucosal integrity testing via HCPCS code C9777, effective October 16, 2025. If your team bills for this procedure, expect denials — Cigna classifies it as experimental.
Cigna Healthcare updated its coverage policy under MM 0577 for the MiVu™ Mucosal Integrity Testing System, a transoral electrical impedance device used during esophagoscopy or esophagogastroduodenoscopy (EGD). The single affected code is HCPCS C9777. Under this coverage policy, Cigna considers the procedure experimental, investigational, and unproven — which means no reimbursement through standard claims, regardless of diagnosis or clinical setting. If your gastroenterology or general surgery billers are using C9777, this policy change is a direct hit to your revenue cycle.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Mucosal Integrity Testing — MiVu™ |
| Policy Code | MM 0577 |
| Change Type | Modified |
| Effective Date | October 16, 2025 |
| Impact Level | High — all C9777 claims subject to denial |
| Specialties Affected | Gastroenterology, General Surgery, Foregut Surgery |
| Key Action | Audit any pending or future C9777 claims before October 16, 2025 and do not submit without a clear payer exception strategy |
Cigna Mucosal Integrity Testing Coverage Criteria and Medical Necessity Requirements 2025
The Cigna mucosal integrity testing coverage policy under MM 0577 is straightforward — and not in your favor. Cigna does not recognize HCPCS C9777 as medically necessary for any indication. The procedure, which measures esophageal mucosal integrity using transoral electrical impedance during an esophagoscopy or EGD, falls entirely outside Cigna's covered services as of the effective date.
There are no coverage criteria to meet here. There is no clinical threshold, no prior authorization pathway, and no exception listed for specific diagnoses like GERD, Barrett's esophagus, or eosinophilic esophagitis. Cigna has drawn a hard line: the MiVu™ system does not have enough clinical evidence behind it to meet their medical necessity standards.
This is not a gray-area policy where prior authorization might get you across the line. Cigna's experimental/investigational classification means the service is excluded from coverage as a category. Submitting C9777 with an authorization doesn't change the outcome — the code itself is the problem.
For billing teams wondering whether Cigna's position on mucosal integrity testing might vary by plan type, the answer from this policy is no. MM 0577 applies across Cigna commercial plans as a coverage policy determination. If you have patients enrolled in Cigna and a physician ordering MiVu™ testing, the financial exposure lands on your practice — or your patient — unless you have a documented advance beneficiary-style notice equivalent and explicit patient consent to pay out-of-pocket.
Cigna Mucosal Integrity Testing Exclusions and Non-Covered Indications
Cigna classifies esophageal mucosal integrity testing by transoral electrical impedance as experimental, investigational, and unproven. That's the language that matters for your denial management workflow. "Experimental" in a Cigna coverage policy is not a soft suggestion — it's a categorical exclusion.
The MiVu™ Mucosal Integrity Testing System is specifically named. This isn't a broad technology exclusion that might leave room for a different manufacturer's device. Cigna has identified this system by name and assigned it a non-covered status.
The real issue here is that experimental designations are extremely difficult to overturn on appeal. You can win a medical necessity appeal if documentation is strong. You almost never win an experimental/investigational appeal unless the payer reverses its own policy — and that requires new peer-reviewed evidence, usually accumulated over years. Don't build an appeal strategy around changing Cigna's mind on C9777 anytime soon.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Esophageal mucosal integrity testing via transoral electrical impedance (MiVu™ system), includes esophagoscopy or EGD | Experimental / Investigational / Unproven — Not Covered | C9777 | No prior authorization pathway. No covered indication. Patient financial liability notice recommended before procedure |
Cigna Mucosal Integrity Testing Billing Guidelines and Action Items 2025
This policy doesn't leave much room for workarounds, but there are concrete steps your billing team should take now.
| # | Action Item |
|---|---|
| 1 | Pull all open C9777 claims before October 16, 2025. Any C9777 claim submitted after the effective date of October 16, 2025 is subject to denial under MM 0577. Check your clearinghouse queue and your biller's worklist today. |
| 2 | Flag C9777 in your charge capture system as non-billable to Cigna. Your EHR or practice management system should block or flag this code for Cigna payers. This is not optional — a single missed flag turns into a denial, a write-off, and lost time on an unwinnable appeal. |
| 3 | Notify ordering physicians about the coverage change. Gastroenterologists and surgeons ordering MiVu™ testing need to know Cigna won't cover C9777. They're likely to find out from a claim denial otherwise. Get ahead of it. A short email to your physician group with the effective date and code is enough. |
| 4 | Implement a financial liability notice process for Cigna patients. If a physician still wants to use the MiVu™ system on a Cigna-insured patient, you need written documentation that the patient understands they will be billed directly. This protects your practice. Work with your compliance officer to confirm the language meets your state's requirements. |
| 5 | Review your contracts for mucosal integrity testing billing. If your group has a Cigna contract that includes bundled procedures or facility agreements, check whether C9777 sits inside a bundled EGD payment or is billed separately. A bundled scenario changes your exposure. If you're not sure how this applies to your facility's billing arrangement, talk to your billing consultant before October 16, 2025. |
| 6 | Don't file appeals based on medical necessity alone. The experimental designation is the barrier — not documentation. Standard medical necessity appeals won't succeed here. If you believe a specific patient has a compelling case, loop in your compliance officer and consider a peer-to-peer review request, but go in with low expectations. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Mucosal Integrity Testing Under MM 0577
The MM 0577 Cigna Healthcare policy lists one code. There are no covered alternatives, no additional CPT codes, and no ICD-10 codes specified in the policy data.
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| C9777 | HCPCS | Esophageal mucosal integrity testing by electrical impedance, transoral; includes esophagoscopy or esophagogastroduodenoscopy | Considered Experimental / Investigational / Unproven by Cigna Healthcare under MM 0577 |
A Note on the Bundled Procedure Language
The C9777 descriptor is explicit: it includes esophagoscopy or EGD. This matters for mucosal integrity testing billing. You cannot unbundle C9777 and bill the scope separately to recover some reimbursement. The procedure code bundles the endoscopic component. If a physician performs a standard EGD and also uses the MiVu™ system, bill the EGD under its standard CPT code and do not add C9777 for Cigna. Adding C9777 triggers the denial. The EGD itself may still be covered under a separate CPT code — that's a different coverage determination entirely.
There are no ICD-10 codes listed in this policy. Cigna's MM 0577 does not specify diagnosis codes that would trigger or modify coverage for C9777. The experimental designation is code-level, not diagnosis-level.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.